Antibodies to SARS-CoV-2 and risk of future sickness

• DOI: 10.1101/2020.09.14.20194308
• Publication Date: 2020-09-18T20:30:25Z
• Authors: Joakim Dillner; K. Miriam Elfström; Jonas Blomqvist; Carina Eklund; Camilla Lagheden; Sara Nordqvist-Kl...; Cecilia Hellström; Jennie Olofsson; Eni Andersson; August Jernbom Falk; Sofia Bergström; Emilie Hultin; Elisa Pin; Anna Månberg; Peter Nilsson; My Hedhammar; Sophia Hober; Johan Mattsson; Laila Sara Arroyo...; Kalle Conneryd Lu...
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Abstract Background The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. Method We analyzed 12928 healthy hospital employees for and compared results participant sick leave records (Clinical trial registration: https:ClinicalTrials.gov NCT04411576 ). Results Subjects with viral serum were not at excess risk (Odds Ratio (OR): 0.85 (95% Confidence Interval (CI) (0.85 (0.43-1.68)). By contrast, subjects had an in the past weeks (OR: 3.34 (2.98-3.74)). Conclusion Presence of marks protection disease.